MICHAEL WHITE to Malaria Vaccines
This is a "connection" page, showing publications MICHAEL WHITE has written about Malaria Vaccines.
Connection Strength
1.217
-
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis. 2015 Dec; 15(12):1450-8.
Score: 0.478
-
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination. Med. 2021 06 11; 2(6):701-719.e19.
Score: 0.178
-
Targets of complement-fixing antibodies in protective immunity against malaria in children. Nat Commun. 2019 02 05; 10(1):610.
Score: 0.152
-
Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda. Vaccine. 2017 02 07; 35(6):873-881.
Score: 0.131
-
Current Mathematical Models for Analyzing Anti-Malarial Antibody Data with an Eye to Malaria Elimination and Eradication. J Immunol Res. 2015; 2015:738030.
Score: 0.122
-
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet. 2016 Jan 23; 387(10016):367-375.
Score: 0.121
-
Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development. Elife. 2017 09 26; 6.
Score: 0.034